Radiopharmaceuticals and contrast media

Application Refer to the product&#8242s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

BTL BLK NM HDPE 125ML 500/CS

BTL MEDIA PYREX 500ML 10/CS

BTLE SQ STE 1000 ML PETG 48/CS

BTLE SQ STE 2000 ML PETG 24/CS

BTLE SQ STE 250 ML PETG 96/CS

Biochem/physiol Actions BTO-1 is a polo-like kinase (Plk) inhibitor.

Biochem/physiol Actions BTO-1 is a polo-like kinase (Plk) inhibitor.

Activator solution, containing powerful activators like 4,5-dicyanoimidazole(DCI), 5-(3,5-bis(trifluoromethyl)phenyl)-1H-tetrazole (Activator 42) or5-(Ethylthio)-1H-tetrazole (ETT) in acetonitrile, are mixed with solutions of phosphoramidites

Application BTTAA is a next-generation, water-soluble ligand for the copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) that dramatically accelerates reaction rates and suppresses cell cytotoxicity. The biocompatibility and fast kinetics of

Application BTTAA is a next-generation, water-soluble ligand for the copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) that dramatically accelerates reaction rates and suppresses cell cytotoxicity. The biocompatibility and fast kinetics of

Application BTTES is a a next-generation, water-soluble ligand for the copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) that accelerates reaction rates and suppresses cell cytotoxicity. The biocompatibility and fast kinetics of BTTES are